Investor Presentaiton
GLP-1 class expansion continues in the US with volume growth
across our portfolio in the fourth quarter of 2022
8
Investor presentation
Full year 2022
US GLP-1 weekly NBRx prescriptions
Weekly NBRX
scripts ('000s)
60
60
50
40
40
30
20
10
Novo NordiskⓇ
US GLP-1 TRX market share
TRX share
Total GLP-1 scripts
(millions)
60%
Class growth -50%
5
50.3%
4
37.2%
40%
3
31.5%
2
20%
16.7%
7.6% 1
5.9%
0%
0
Jan
2023
Jan
2021
Jan
2023
VictozaⓇ
NN GLP-1
dulaglutide tirzepatide
Total monthly GLP-1 scripts
0
Jan
2021
Ozempic RybelsusⓇ
Source: IQVIA Xponent, NBRX data from week ending 13 Jan 2023. TRX data from week ending 13 Jan 2023. Each data points represents a rolling four-week average
NBRX: New-to-brand prescriptions; TRX: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions
Note: Class growth calculated as Q4 2022 vs Q4 2021View entire presentation